Details for Patent: 10,452,815
Which drugs does patent 10,452,815 protect, and when does it expire?
Patent 10,452,815 protects FINTEPLA and is included in one NDA.
Protection for FINTEPLA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-four patent family members in fifteen countries.
Summary for Patent: 10,452,815
| Title: | Control system for control of distribution of medication |
| Abstract: | A system of controlling distribution of a medication in the treatment or prevention of epilepsy is provided. A central controller of the system has a data store and one or more processors for reading and writing data to the data store. The data store comprises a database of patient records, each patient record having a medication authorization field. The central controller can output an authorization of a first prescription of epilepsy medication to a patient in dependence upon genetic test results for the patient and schedules a subsequent test for the patient prior to authorization of a subsequent prescription of epilepsy medication. Also provided are methods in which the subject systems find use. The systems and methods find use in the treatment of severe subtypes of epilepsy or refractory epilepsy, such as Dravet Syndrome. |
| Inventor(s): | Richard Alistair Balfour STEWART, Anthony Clarke |
| Assignee: | Zogenix International Ltd |
| Application Number: | US14/867,862 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,452,815 |
|
Patent Claim Types: see list of patent claims | Use; Compound; Device; |
Drugs Protected by US Patent 10,452,815
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | FINTEPLA | fenfluramine hydrochloride | SOLUTION;ORAL | 212102-001 | Jun 25, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,452,815
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015326472 | ⤷ Start Trial | |||
| Australia | 2020202655 | ⤷ Start Trial | |||
| Brazil | 112017006219 | ⤷ Start Trial | |||
| Canada | 2962367 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
